KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Total Non-Current Liabilities (2016 - 2021)

Palvella Therapeutics (PVLA) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $47.0 million as the latest value for Q2 2023.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $47.0 million in Q2 2023 year-over-year; TTM through Jun 2023 was $47.0 million, a N/A change, with the full-year FY2022 number at $67.6 million, down 34.28% from a year prior.
  • Total Non-Current Liabilities was $47.0 million for Q2 2023 at Palvella Therapeutics, down from $67.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $110.3 million in Q3 2021 to a low of $47.0 million in Q2 2023.
  • A 5-year average of $87.4 million and a median of $89.7 million in 2019 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 38.97% in 2021, then crashed 34.28% in 2022.
  • Palvella Therapeutics' Total Non-Current Liabilities stood at $89.7 million in 2019, then decreased by 17.57% to $74.0 million in 2020, then skyrocketed by 38.97% to $102.8 million in 2021, then plummeted by 34.28% to $67.6 million in 2022, then crashed by 30.37% to $47.0 million in 2023.
  • Per Business Quant, the three most recent readings for PVLA's Total Non-Current Liabilities are $47.0 million (Q2 2023), $67.6 million (Q4 2022), and $102.8 million (Q4 2021).